M&A / Deals Daiichi exits OTC, with $1.55bn unit sale to Suntory PharmaphorumDaiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.M&A / DealsRead full story pharminent April 15, 2026 Pharmaphorum Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies. M&A / DealsRead full story Post navigation Previous: BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debutNext: Parkinson’s charity partners Biognosys on biomarker project Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026